KaydedilenlerDerginizi ekleyin

Dergiler / Medicine Science / 2017 / Cilt: 6 - Sayı: 3

The effect of vitamin B12 deficiency on the GH-IGF1 axis

BELMA HALİLOĞLU
GÜLEN TÜYSÜZ KİNTRUP
Avni KAYA
Sayfa
496–497
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, there is a need for the studies that are performed in children with more severe and long-term B12 deficiency

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Vitamin B12 (B12) deficiency is associated with growth retardation, reduced serum osteocalcin levels, lower bone mineral density, and increased bone fracture risk, yet the underlying mechanisms remain unclear.
📊
Temel Bulgular & Veri:However, a recent study showed that B12 positively regulates postweaning growth and bone formation via taurine.
💡
Sonuç & Katkı:However, there is a need for the studies that are performed in children with more severe and long-term B12 deficiency
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Vitamin B12 (B12) deficiency is associated with growth retardation, reduced serum osteocalcin levels, lower bone mineral density, and increased bone fracture risk, yet the underlying mechanisms remain unclear. However, a recent study showed that B12 positively regulates postweaning growth and bone formation via taurine. B12 deficiency causes growth hormone resistance (GH) and IGF1 (Insulin-like growth factor-1) deficiency. In the present study, we aimed to evaluate the effect of B12 deficiency on the axis of GH-IGF1 and serum taurine level. Eighteen children with B12 deficiency (B12 düzeyi 20 kg 1000 mcg/day). The mean age of the 18 subjects (6F/12M) was 8.0±4.8 years-old. The levels of serum B12, growth hormone, IGF1, IGFBP3 and taurine before and after oral B12 treatment were 132.6±28.4 pg/ml vs 655.8±384.4 pg/ml, 1.20±1.98 vs 1.35±1.20 ng/ml, 213.9±185.8 vs 217.8±181.5 ng/ml, 3683.5±1497 vs 3583.5±1207.3ng/ml, 32.7±18.0 vs 41.1±30.4 μmol/L (p<0.0001,p=0.41,0.37,0.28 ve 0.31, respectively). The present study did not detect any relation between B12 deficiency and the GH-IGF1 axis. However, there is a need for the studies that are performed in children with more severe and long-term B12 deficiency

🔖

Bu Makaleye Atıf Yap

HALİLOĞLU, B., KİNTRUP, G. T., KAYA, A. (2017). The effect of vitamin B12 deficiency on the GH-IGF1 axis. Medicine Science, Cilt: 6 - Sayı: 3, 496–497. https://ajindex.com/articles/277456

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Kalhan SC, Marczewski SE. Methionine, homocysteine, one carbon metabolism and fetal growth. Rev Endocr Metab Disord. 2012;13(2):109–19
  2. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(21):2041-2
  3. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, Kiel DP. Low plasma vitamin B12 is associ- ated with lower BMD: the Framingham Osteopo- rosis Study. J Bone Miner Res. 2005;20(1):152-8
  4. Muthayya S, Kurpad AV, Duggan CP, Bosch RJ, Dwarkanath P, Mhaskar A, Mhaskar R, Thomas A, Vaz M, Bhat S, Fawzi WW. Low maternal vitamin B12 sta- tus is associated with intrauterine growth retarda- tion in urban South Indians. Eur J Clin Nutr. 2006;60(6):791-801
  5. Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, Crane J, Frassica F, Zhang L, Rodriguez JP, Xiaofeng Jia, Shoshana Yakar, Shouhong Xuan, Argiris Efstratiadis, Mei Wan, Xu Cao. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012;18(7):1095–101
  6. Verner A, Craig S, McGuire W. Effect of taurine supplementation on growth and development in preterm or low birth weight infants. Cochrane Data-base Syst Rev. 2007;4:CD006072
  7. Roman-Garcia P, Quiros-Gonzalez I, Mottram L, Lieben L, Sharan K, Wangwiwatsin A, Tubio J, Lewis K, Wilkinson D, Santhanam B, Sarper N, Clare S, Vassiliou GS, Velagapudi VR, Dougan G, Yadav VK. Vitamin B₁₂-dependent taurine synthesis regulates growth and bone mass. J Clin Invest. 2014 Jul;124(7):2988-3002